JAMA
JAMA is the American Medical Association's flagship journal. It is strong on cancer screening, prevention, health-services and patient-reported-outcome research, and on the USPSTF recommendations.
JAMA is a weekly general-medicine journal. In oncology it carries screening and prevention trials, the US Preventive Services Task Force recommendation statements, health-policy and drug-pricing analyses, and landmark care-delivery studies such as Basch's 2017 electronic symptom-monitoring survival result. Hybrid access; research articles are free to read after 12 months.
Routinely asking patients how they feel between visits, and acting on the answers, is a treatment in itself. It catches problems early, keeps people on effective therapy longer and appears to extend life. Cancer centres now build symptom monitoring into electronic records, though implementation is uneven.
For women who carry a BRCA mutation, preventive removal of the ovaries and tubes saves lives, and preventive mastectomy almost eliminates breast cancer. These are the strongest prevention effects in oncology, which is why finding carriers before they develop cancer matters so much.
GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.
Breast oncologist who co-leads SWOG and studies adherence, toxicity, and how care is actually delivered.
Breast oncologist who led key ADC and CDK4/6 trials and moved from UCSF to City of Hope in 2024.
Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.
Julie Park led the COG trial that made tandem transplant standard for high-risk neuroblastoma.
Breast surgeon who built the I-SPY platform, the adaptive trial that tests new drugs before surgery.
Led the EORTC/NCIC trial that made temozolomide with radiotherapy the glioblastoma standard, and the EF-14 trial of tumour treating fields.
Leads CIRCULATE-Japan, the largest ctDNA-guided adjuvant programme in colorectal cancer, and the PARADIGM and SCRUM-Japan GI efforts.
Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.